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Abstract
Background:  Understanding risks is considered to be crucial for informed decision-making.
Inaccurate risk perception is a common finding in women with a family history of breast cancer
attending genetic counseling. As yet, it is unclear how risks should best be communicated in clinical
practice. This study protocol describes the design and methods of the BRISC (Breast cancer RISk
Communication) study evaluating the effect of different formats of risk communication on the
counsellee's risk perception, psychological well-being and decision-making regarding preventive
options for breast cancer.
Methods and design: The BRISC study is designed as a pre-post-test controlled group
intervention trial with repeated measurements using questionnaires. The intervention-an additional
risk consultation-consists of one of 5 conditions that differ in the way counsellee's breast cancer
risk is communicated: 1) lifetime risk in numerical format (natural frequencies, i.e. X out of 100),
2) lifetime risk in both numerical format and graphical format (population figures), 3) lifetime risk
and age-related risk in numerical format, 4) lifetime risk and age-related risk in both numerical
format and graphical format, and 5) lifetime risk in percentages. Condition 6 is the control
condition in which no intervention is given (usual care). Participants are unaffected women with a
family history of breast cancer attending one of three participating clinical genetic centres in the
Netherlands.
Discussion: The BRISC study allows for an evaluation of the effects of different formats of
communicating breast cancer risks to counsellees. The results can be used to optimize risk
communication in order to improve informed decision-making among women with a family history
of breast cancer. They may also be useful for risk communication in other health-related services.
Trial registration: Current Controlled Trials ISRCTN14566836.
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Background
Risk communication aims to improve people's under-
standing of health risks in order to contribute to informed
decision-making. Of particular interest and complexity
are risks regarding hereditary or familial cancer, such as
breast/ovarian or colon cancer [1]. It is commonly
assumed that 5–10% of all breast cancer cases can be
attributed to a genetic predisposition, of which the breast
cancer genes BRCA1 and BRCA2 have been identified as
most important [2]. Mutations in these genes increase the
lifetime risk of breast cancer substantially, e.g. from a 10%
population risk [3] to a risk of 60–85% of developing can-
cer by age 70 [4,5]. However, BRCA1/2 mutations account
for only a small subgroup of women with a family history
of breast cancer. A substantial group of women attending
genetic counselling because of their family history have a
slightly (11–20%) or moderately (20–30%) increased risk
of getting breast cancer. Genetic counselling generally
takes place at specialised centres and focuses on the com-
munication of personalised risk information. The aim is
to have a well-informed counsellee, who understands
both risks and consequences, and acts accordingly [6].
The multiple risks and uncertainty of the risks, e.g.
because of the incomplete penetrance of BRCA1/2 muta-
tions, introduces complexity into risk communication
regarding hereditary and familial breast cancer. Based on
these complex risk contexts, decisions have to be made
such as whether and when to start mammography screen-
ing, and, assuming eligibility, whether to test for muta-
tions in BRCA1/2, and subsequent decisions in the case of
positive or negative genetic test-outcome. Understanding
risks is considered to be crucial for informed decision-
making [7], whereas inappropriately high (or low) per-
ceptions of risk can lead to various and potentially harm-
ful decisions, for example overscreening due to
overestimation of risk [8]. Overestimation of risk is also
shown to be positively correlated with breast cancer
worry, which may affect psychological well-being nega-
tively [9]. Previous studies found a high percentage of
unaffected women with a family history of breast cancer
overestimating their breast cancer risk, although underes-
timating also occurred (see review [10]). In general,
genetic counselling decreases generalized anxiety [11],
and significantly improves the accuracy of women's per-
ceptions of their breast cancer risk [11,12], but not neces-
sarily to the correct level [11], or for the long term [12].
Therefore, it is important to identify strategies that will
optimize understanding of risk.
Risk communication in genetic counselling is difficult,
not only due to the complexity of the risks involved, but
also due to problems that counsellors themselves experi-
ence in conveying these risks in an understandable way
[13]. In addition, the counsellee's understanding and
retention of the information given may be problematic.
Personal experiences with breast cancer and counsellee's
personal characteristics could have mediating effects on
the efficacy of risk communication. For instance, the
impact of a woman's family history can influence her risk
perception prior to counselling through phenomena such
as "anchoring" or availability heuristics [14]. Addition-
ally, people with a high need for cognition potentially
process risk information more thoroughly and have a
higher need for additional risk information compared
with people with a low need for cognition [15]. Moreover,
women who face difficult decisions with respect to, for
instance, genetic testing, may cope differently as a result of
their dispositional decision-coping patterns [16].
Regarding the risk communication process, research has
shown that the context and format in which genetic risks
are presented affect people's risk perception, and their
subsequent decisions [17,18]. Although risk presented in
numeric terms are precise and preferred by healthy coun-
sellees [19] and patients [20], risks in verbal terms (e.g. "a
high risk") are generally more familiar and easier to
understand. However, the inherent vagueness of verbal
risks leads to substantial variation in their interpretation
[21,22]. Risks presented frequentistically (e.g. "1 in 10
cases"), may result in more accurate risk perception and
better-founded decisions compared with risks presented
in percentages [23]. When frequencies are used, rates (i.e.
X in 100) are easier to understand than proportions (i.e. 1
in X) when comparing risks [24]. In sum, both numerical
and verbal formats have their pros and cons (see also Lip-
kus [25]). Several recommendations have been made
directed at the use of graphical displays in risk communi-
cation [25,26], which may provide helpful support, par-
ticularly for persons with low cognitive capacity such as
low levels of numeracy [26,27]. Baty et al., for example,
reported that graphical displays enabled women to
quickly understand their risks of getting breast cancer
[28]. However, others have shown that risks presented as
icons or pictographs (e.g. population figures in 10 rows of
10) did not result in a better understanding, while having
a higher affective impact, and were perceived as larger
compared to numerical formats [18,29].
Furthermore, the time horizon in which risks are pre-
sented is relevant. Time horizons may raise confusion,
especially for long-term cumulative risks such as lifetime
breast cancer risks [30]. Short-term risks such as risks for
the next ten years may therefore be more meaningful and
immediate [30], and may result in less overestimation.
Research showed that for the presentation of breast cancer
risks, women preferred risk information framed over mul-
tiple time horizons (10-year-, 20-year- and lifetime hori-
zons) to risk information framed at one time point [31].
Until now, most studies used hypothetical scenarios inBMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
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exploring patients' preference for the manner in which
risk information is given. However, it is important to dis-
cover the best format for communicating cancer risk infor-
mation in practice tailored to individual counsellees [26].
Several dimensions or outcomes in evaluating the effec-
tiveness of the risk communication process have been dis-
tinguished [25,32,33]. Among these dimensions are,
firstly, a cognitive evaluation, which refers to risk percep-
tion, and understanding and recalling the information
provided. Acquisition of knowledge in the context of
familial breast cancer comprises of understanding the
nature of (familial) breast cancer, knowledge of personal
risk factors, understanding the probability of developing
breast cancer when having a genetic predisposition, and
understanding what actions can be taken to reduce the
risk. A second dimension is psychological well-being,
including affective reactions and concern, for example,
anxiety, (breast cancer) worries, and intrusive thoughts. A
third dimension is the decision-making process including
a behavioural evaluation, for example with regard to
adherence to recommended behaviours (e.g. monthly
breast self-examinations, mammography screening) and
other decisions such as informing relatives who may be at
risk. Finally, another dimension is how counsellees evalu-
ate the information that is provided, which includes the
extent to which the risk information is regarded as helpful
and clear by counsellees.
Currently, protocols in genetic counselling for breast can-
cer contain no guidelines for the optimal format of risk
communication. Therefore, counsellors present risks in
ways that seem right to them despite a lack of evidence to
support this [13]. Observational research shows that in
breast cancer counselling, risks are given at least half of the
time in verbal terms [34,35], and in 25% of the consulta-
tions in percentages [36].
In the Netherlands, current information booklets on
hereditary breast cancer to support genetic counselling
generally present risks, e.g. chance of developing breast
cancer, as absolute percentages with a long-term time
horizon ('lifetime risk'). In genetic counselling, generally
the same formats are used, although one study recently
revealed that a time horizon is not often stated in breast
cancer counselling [35]. In addition, age-related risks
regarding breast cancer counselling are usually not com-
municated, although in other countries, such as the UK,
age-related risks are more commonly used [19].
Objectives and research questions
The main objective of the present study is to evaluate the
effects of different formats of risk communication on the
counsellee's understanding and perception of the risk
(cognitive outcomes), psychological well-being, and deci-
sion-making. In particular, we aim to investigate numeri-
cal versus graphical risk formats and lifetime breast cancer
risks versus age-related risks. The research questions are:
1) What is the effect of the addition of a graphical format
to standard risk information on cognitive outcomes, psy-
chological well-being, and decision-making?
2) What is the effect of the addition of an age-related for-
mat to standard risk information on cognitive outcomes,
psychological well-being, and decision-making?
3) What is the effect of the combination of both the addi-
tion of a graphical format and the addition of an age-
related format on outcomes compared to research ques-
tions 1 and 2 (i.e. effect modification/interaction)?
4) How do the counsellee's personal experiences and
characteristics mediate the effect on the communication
of risk?
This article describes and discusses both the design and
the content of the intervention of the BRISC (Breast cancer
RISk Communication) study, a multicentre controlled
clinical trial, to optimise the communication of breast
cancer risks in genetic counselling among women with a
family history of breast cancer.
Methods and design
Study design
The BRISC study is designed as a pre-post-test controlled
group intervention trial with repeated measures using
questionnaires. The trial is carried out in three of the nine
familial cancer clinics in the Netherlands. The Medical
Ethics Committees of the VU University Medical Center
Amsterdam, the University Medical Center Groningen,
and the Leiden University Medical Center approved the
protocol in 2005.
Intervention
The intervention consists of one additional consultation
by a trained "risk counsellor" immediately after a stand-
ard genetic counselling session with a clinical geneticist, a
clinical geneticist in training, or non-medical genetic
counsellor, henceforth defined as a "genetic counsellor"
(Figure 1). Since genetic counselling is seen as a psycho-
educational endeavour with both educational and thera-
peutic elements [37], it is considered unethical to ask the
genetic counsellors to present the intervention in a stand-
ardized and as objective a way as possible, thereby ignor-
ing the specific needs of the patient. In addition, we
assume that besides being unethical, it will not be feasible
due to an additional workload for genetic counsellors.BMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
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During the additional consultation, risks are communi-
cated in one of five ways (conditions), namely:
1) lifetime breast cancer risk in numerical format (in nat-
ural frequencies, i.e. X out of 100),
2) lifetime breast cancer risk in both numerical format
and graphical format (i.e. population figures in 10 rows of
10),
3) lifetime breast cancer risk and age-related breast cancer
risk in numerical format,
4) lifetime breast cancer risk and age-related breast cancer
risk in both numerical format and graphical format, and
5) lifetime breast cancer risk in percentages.
Since the information given during the intervention not
only differs from usual care regarding the format of the
risks but also to the extent to which the information is
structured, two control conditions are included. Condi-
tion 5, in which the risk is communicated in percentages
as in the standard genetic counselling session (usual care),
controls for the effect of giving risk information also in a
structured way, enabling us to compare the effects of dif-
ferent risk formats. Condition 6, in which no intervention
is given (usual care, henceforth defined as the control
group) is used to control for the effect of repetition of the
risk information (as compared to condition 5), and will
control for Hawthorne effects [38].
As is shown in Table 1, the intervention includes informa-
tion about risks of developing breast cancer, and having a
hereditary predisposition for breast cancer. This includes:
risk for an "average" woman in the Netherlands (popula-
tion risk), risk for women with a BRCA1/2 mutation (car-
riers), and risk for women with the same family history as
the counsellee. An example of risk information given in
condition 1 is: "On average, 10 out of every 100 women
Time planning of the intervention and questionnaires in the intervention group (conditions 1–5) and control group (condition  6) Figure 1
Time planning of the intervention and questionnaires in the intervention group (conditions 1–5) and control 
group (condition 6).
T0                 T1       T2 (2 weeks)     T3 (6 months)  
    
T0                          T1C (2 weeks)     T2C (6 months)   
Standard genetic 
counselling 
session
Intervention 
(conditions 1-5) 
Standard genetic 
counselling 
session
Intervention 
group 
Control  
group 
Table 1: Overview of risk information communicated in the intervention
Population risk:
Lifetime breast cancer risk: 10 out of 100 for breast cancer patients
Breast cancer risk due to hereditary causes: 5 to 10 out of 100
Carriers of BRCA1/BRCA2 mutation:
Lifetime breast cancer risk: 60 to 80 out of 100
Risk passing a BRCA1/BRCA2 mutation to children: 50 out of 100
Women with the same family history:
Lifetime breast cancer risk:
- 11–20 out of 100 for women in a low risk category
- 20–30 out of 100 for women in a moderate risk category
- 30–40 out of 100 for women in a high risk category
Risk having a BRCA1/BRCA2 mutation: less than 10 out of 100 and specified if more than 10 out of 100BMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
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in the Netherlands will develop breast cancer during their
lifetime". In conditions 3 and 4, not only the structure of
a cumulative risk is explained, but also age-related risks
are presented (Figure 2). These age-related risks are com-
puted based on Jonker et al. [39] and comprise breast can-
cer risks for the next ten years. An example of condition 3
is "In the current situation, on average 2 out of 100
women in the Netherlands of the same age as you (40),
will develop breast cancer in the next ten years". In condi-
tion 2 and 4 risks are also presented as graphical display
(see for example Figure 3).
Usual care
In line with the guidelines of the Dutch Society of Clinical
Genetics, genetic counselling generally includes informa-
tion on the counsellee's lifetime breast cancer risk com-
pared with the lifetime population risk [40]. Based on the
individual lifetime risk, three breast cancer risk groups are
distinguished: low (11–20%), moderate (20–30%), and
high (30–40%). These estimates are mostly calculated
using the Claus tables and modified Claus method, and
primarily based on a woman's age and family history,
including the number of first-degree- or second-degree
relatives with breast cancer and the ages of onset of breast
cancer [41].
Based on these guidelines, consensus is reached for the
study to standardize the content and structure of the
standard genetic counselling sessions (usual care) by pre-
senting the woman's breast cancer risk as one of three risk
groups, and using percentages for presenting risks. A
"counselling checklist" is designed to be used as a guide-
line during the counselling session. The standard counsel-
ling procedures will be discussed with all counsellors
involved.
Study population
Women with a family history of breast cancer who are
first-time attendees applying for breast cancer counselling
are invited to participate in the study. A family history of
breast cancer is defined as having or having had at least
one first-degree- and/or paternal second-degree family
member with breast cancer. Women are considered ineli-
gible if they are under 18 years of age, have evident psychi-
atric illness or terminal disease, and are unable to read
and write Dutch. Women with a personal history of breast
or ovarian cancer are also excluded, because of the com-
plexities in risk counselling of women with a previous his-
tory of cancer. Participants are allocated into an
intervention or control group (for randomisation proce-
dure, see below). Stratification to first-degree family mem-
bers is applied to ensure that all family members receive
the same condition.
Sample size and power
The study will be powered on the main outcome measure,
namely (change in) risk perception. In order to be able to
detect a clinically relevant difference of 10–20% differ-
ence between the intervention group and the control
group, a sample of 60 women per condition is needed
(total n = 360). These calculations are based on a power
of 0.80 (1-β) and a significance level of 0.05 (a; two-
sided). With an expected drop-out rate of 20%, the sample
size for the study is therefore determined at 450. Recruit-
ment and data collection (including follow-up) is antici-
pated to continue for 31 months.
Risk communication formats in conditions 1–4 Figure 2
Risk communication formats in conditions 1–4.
Numerical 
risk format 
Numerical & 
graphical risk format 
Lifetime risk  Condition 1  Condition 2 
Lifetime risk & 
age-related risk Condition 3  Condition 4 BMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
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Randomisation
Randomisation takes place at 'condition round' level. The
inclusion period is divided into condition rounds using a
Latin Square design. Every round takes 5 months and
switches when a total of n = 75 is reached. The ranking
order of conditions (1–5) is varied to correct for learning
effect by the risk counsellors. Each condition is given
according to the design shown in Table 2. The control
group (condition 6) is constructed in addition to each
condition round.
Procedure
Women applying for genetic breast cancer counselling are
invited to participate by means of an information letter
send to their home address. All participants provide writ-
ten informed consent. In the intervention group, partici-
pants receive a self-administered questionnaire at four
points in time (T0, T1, T2, T3), the control group receives
this at three points in time (T0, T1C, T2C) (see Figure 1):
- T0 (baseline): The women will receive the first question-
naire at home before their first appointment with the
genetic counsellor.
- T1 (after standard counselling session): A second ques-
tionnaire will be given after the standard genetic counsel-
ling session with the genetic counsellor and prior to the
intervention (additional counselling with the risk coun-
sellor).
- T2/T1C (2 weeks follow-up): A third questionnaire will
be sent to the woman's home address at 2 weeks after the
intervention, or a comparable point in time (control
group).
- T3/T2C (6 months follow-up): The final questionnaire
will be sent to the woman's home address.
A maximum of two reminders is sent to participants not
returning their questionnaires. The three risk counsellors
(one for each clinical genetics centre) who provide the
intervention, have been specifically trained for this study.
The intervention lasts for approximately 30 minutes. The
risk counsellor is informed about the content of the previ-
ous standard counselling session by means of a "checklist
after standard counselling", which the genetic counsellor
fills in immediately after each session. This checklist
includes information about the participant's risks e.g.
individual estimated risk of getting breast cancer, also
describing the risks formats that were used during coun-
selling. When risks are not yet known, because, for
instance, medical records need to be checked, interven-
tion takes place after a second visit. Thus, enforcement of
an intervention implies that in the genetic counselling ses-
sion with the genetic counsellor at least the woman's
breast cancer risk group (e.g. low, moderate, high) was
communicated.
Example of graphical risk format used in condition 4 Figure 3
Example of graphical risk format used in condition 4. 
"In the current situation, on average 2 out of 100 women in 
the Netherlands of the same age as you (40), will develop 
breast cancer in the next ten years"
cccccccccc
cccccccccc
cccccccccc
cccccccccc
cccccccccc
cccccccccc
cccccccccc
cccccccccc
cccccccccc
cccccccccc
Table 2: Latin square design of condition rounds over time at the three clinical genetic centres
Conditionsa
months 1–5 months 6–10 months 11–15 months 16–20 months 21–25
Centre A 1 2 3 4 5
Centre B 2 3 4 5 1
Centre C 5 1 2 3 4
a. 1) lifetime risk in numerical format (natural frequencies); 2) lifetime risk in both numerical format and graphical format (population figures); 3) 
lifetime risk and age-related risk in numerical format; 4) lifetime risk and age-related risk in both numerical format and graphical format; 5) lifetime 
risk in percentages. Condition 6 (control group) is constructed in addition to each condition round.BMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
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After the intervention, all participants receive a BRISC bro-
chure in which risks are presented corresponding to the
format of the intervention given.
Measures
Outcome measures
Outcome measures are classified in four dimensions: 1)
cognitive outcomes; 2) psychological well-being; 3) deci-
sion-making; 4) evaluation of the intervention (i.e. addi-
tional risk consultation). Table 3 shows which variables
are measured in which questionnaires.
Cognitive outcomes
Risk perception (primary outcome measure). Table 4 shows
the risk perception measures used in the BRISC study. The
graphical scales, i.e. Visual Analogue Scales (VAS scales)
and graphical display, are only used as a measure after the
intervention, to avoid participants of conditions 2 and 4
being triggered before the additional counselling session.
Recall is assessed by asking women to what breast cancer
risk group they belong: 1 (not increased risk group) to 5
(very strongly increased risk group). Two additional
answering categories are "this has not been discussed" and
"don't know (anymore)".
Knowledge of familial breast cancer is measured by using a
10-item questionnaire based on questionnaires designed
by Lerman et al. [42] and Bluman et al. [43]; adapted and
supplemented with items regarding breast cancer (age-
related) risk. An expert panel (FM, JO, CA) evaluated the
questionnaire using a "true", "false" and "don't know"
answering scale, and consensus was reached on the items
used (Table 5).
Psychological well-being
Breast cancer-related worries about the risk of developing
cancer and the impact of worry on daily functioning is
measured by an 8-item adapted Lerman Cancer Worry
Scale (CWS) [44].
Table 3: Outcome measures of the BRISC study in the different questionnaires
Variables Instruments Questionnaires
T0 T1 T1C T2 T3/T2C
Cognitive outcomes
Risk perception
- numerical scales X X X X X
- verbal scales XXX XX
- graphical scales XX X
Recall X
Knowledge of familial breast cancer X X X X X
Psychological well-being
Cancer-related worries CWS X X X X X
Cancer-related distress and anxiety IES X X
Affect PANAS X X X X X
State anxiety STAI-state X X X X X
Anxiety and depression HADS X X X X X
Decision-making
Intention XXX XX
Behaviour XX
Informed choice MMIC
- attitudes towards DNA testing XX
- genetic test-uptake XX X
Decisional conflict DCS X X X
Evaluation of the intervention XX
Personal characteristics
Sociodemographic characteristics X
Impact of family history XX
Severity of breast cancer IPQ-RAR X X
Perceived Personal Control PPC X X X X
Coping UCL X
General anxiety STAI-trait X X
Need for cognition NCS X X
Cognitive ability CRT X
Decision-making style Melbourne DMQ X
Social support SEC X XBMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
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Breast cancer-related distress and anxiety is measured by a
Dutch version of the 15-item Impact of Events Scale (IES)
[45].
Affect, which can be subdivided into positive affect and
negative affect (distress), is measured by the 20-item
PANAS Scale (Positive and Negative Affect Schedule) [46].
Participants will be instructed to answer the questions in
the context of "the past few days".
State anxiety is measured by a Dutch version of the 6-item
version of the State scale of the Spielberger State-Trait Anx-
iety Inventory (STAI) [47].
Table 4: Risk perception as measured in the BRISC study
Risk perception Numerical scales Verbal scales Graphical scales
X out of 100 % Rating scalea Graphical displayb VAS scale
Population risk
Lifetime breast cancer risk in the general 
population
X X Very small – very large X X
Risks among carriers
Lifetime breast cancer risk in carriers X X Very small – very large X X
Risk passing a BRCA1/BRCA2 mutation to children X X Very small – very large
Participant's risks
Perceived risk of having a hereditary predisposition 
to breast cancer
X X Very small – very large Easy to imagine 
– hard to imagine
Perceived lifetime breast cancer risk X X Very small – very large
Easy to imagine – hard to imagine
Very unlikely – very likely
Perceived age-related breast cancer risk 
(next ten years)
X X Very small – very large Easy to imagine 
– hard to imagine
Very unlikely – very likely
Appraisal of perceived breast cancer risk, 
independent of actual risk
Very small – very large Very unfearful 
– very fearful
Not worrisome at all – very 
worrisome
Perceived breast cancer risk compared to the 
average Dutch Woman
Very strongly lowered – very strongly 
heightened
Risks among women with the same family 
history and age
Lifetime breast cancer risk in women with the same 
family history and age
XX X
Age-related breast cancer risk in women with the 
same family history and age (next ten years)
XX X
a.Rating scales from (1) – (7) except for: Very strongly lowered (1) – very strongly heightened (9).
b.Figure of 100 women.
Table 5: Knowledge questions of familial breast cancer
Items True (T)/
False (F)
1 There is more than one gene that can increase the risk of breast cancer T
2 With hereditary breast cancer, breast cancer develops generally more likely at a younger age compared to non-hereditary breast 
cancer
T
3 A father can pass down a genetic predisposition for breast cancer to his daughter T
4 Even if a woman doesn't have a genetic predisposition for breast cancer, her children still can get the genetic predisposition from 
their grandmother (their mother's mother)
F
5 Regular breast cancer screening can prevent the development of breast cancer F
6 A DNA test can determine whether one will or will not certainly develop breast cancer F
7 Genetic inheritance is the main cause of breast cancer in most patients with breast cancer F
8 All women who have a genetic predisposition for breast cancer will get cancer F
9 With ageing, the residual risk of getting breast cancer becomes smaller T
10 The risk of getting breast cancer within the next ten years is equal to the total lifetime risk of getting breast cancer FBMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
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Anxiety and depression is measured by a Dutch translation
of the 14-item Hospital Anxiety and Depression Scale
(HADS), using the timeframe of "last week" [48].
Decision-making
Intention is measured using 7 self-developed items regard-
ing: breast self-examination; adherence to population
mammography screening (above 50 years of age); breast
screening by a physician every 6 months; mammography
screening every year (own initiative); DNA testing; having
a preventive breast operation (mastectomy); informing
close relatives. Each item has a 7-point scale: 1 (definitely
not) to 7 (definitely), and an additional category "not
applicable".
Behaviour is measured by 6 items using a timeframe of
"the last 6 months", regarding: breast self-examination;
adherence to population screening; breast screening by a
physician; mammography screening (own initiative);
consulting a specialist about a preventive breast opera-
tion; preventive breast operation.
Informed choice with regard to genetic testing, which is based
on knowledge, attitudes, genetic test uptake and value
consistency, is assessed using a multi-dimensional meas-
ure of informed choice (MMIC) developed by Marteau
[49] and extended by Van den Berg [50]. Attitudes
towards having a DNA test for breast cancer is measured
by two items with a 7-point rating scale ranging from 1
(bad) to 7 (good) and from 1 (useless) to 7 (useful).
Genetic test uptake is measured at follow-up (T2/T1C and
T3/T2C). To determine value consistency, attitude scores
will be combined with test uptake [50].
Difficulties in decision-making or decisional conflict are meas-
ured by the Dutch version of the Decisional Conflict Scale
(DCS) of O'Conner [51].
Evaluation of the intervention
The extent to which the additional risk information (inter-
vention) is regarded as useful for decision-making, threat-
ening, and easy to understand was assessed using a 7-
point rating scale. Satisfaction with the information pro-
vided is measured by a 7-point response format, ranging
from 1 (very dissatisfied) to 7 (very satisfied).
Personal experiences and characteristics
Several personal characteristics and experiences are meas-
ured which may have mediating effects on the efficacy of
risk communication.
Sociodemographic characteristics included age, level of edu-
cation, marital status, parent's country of birth, number of
children, religious affiliation.
Impact of family history is measured using 4 self-developed
items regarding: the number of family members that have
or have had breast cancer (including the family relation-
ship); perceived impact of this experience by a 7-point
scale ranging from 1 (no strong impact) to 7 (very strong
impact); the effect of this experience on perceived anxiety
regarding getting breast cancer by a 7-point scale ranging
from 1 (no strong effect) to 7 (very strong effect); the
extent to which the subject "hereditary breast cancer"
plays a part in the family by a 7-point scale ranging from
1 (not at all) to 7 (very).
Severity of breast cancer is measured by 6 items on the Con-
sequences Subscale of the Dutch version for at-risk indi-
viduals of the Revised Illness Perception Questionnaire,
that is IPQ-RAR [52].
Perceived Personal Control is measured by a Dutch transla-
tion of the Perceived Personal Control questionnaire
(PPC) [53].
Coping is measured by the 19-item Utrecht Coping List
(UCL) [54].
General anxiety is measured by a 20-item version of the
Dutch version of the Trait scale (STAI-form Y) of the Spiel-
berger State-Trait Anxiety Inventory (STAI) [55].
Need for Cognition can be described as an "individual dis-
position to engage in and enjoy thinking", and is meas-
ured by an 18-item Dutch version of the Need for
Cognition Scale (NCS) [15].
Cognitive ability is measured using the 3-item Cognitive
Reflection Test (CRT) [56].
Decision-making style is measured by the 22-item Mel-
bourne Decision Making Questionnaire (Melbourne
DMQ) [57].
Social support is measured by the 16-item Social Experi-
ences Checklist (SEC) [58].
Statistical analyses
Analyses will be performed to estimate the effect of the
different interventions (formats) by comparing pre-test-
(T0/T1) with post-test- (T2/T1C) outcome measures
between the five different intervention groups and the
control group, using multivariate analyses. At baseline
(T0) and at T1 similar variables will be measured in order
to be able to assess the effect of the regular counselling ses-
sion with the genetic counsellor. Personal variables will
be included as covariates. Repeated measures in
MANOVA will be used to analyse changes over time and
long-term effects (T3/T2C).BMC Cancer 2008, 8:283 http://www.biomedcentral.com/1471-2407/8/283
Page 10 of 12
(page number not for citation purposes)
Discussion
Understanding risks is considered to be crucial for
informed decision-making. However, inaccurate risk per-
ception is a common finding in women attending genetic
counselling regarding breast cancer. Although the litera-
ture provides recommendations for the use of frequencies,
graphical displays and short-term risks such as age-related
risks (i.e. risks for the next ten years) in risk communica-
tion, these recommendations are based primarily on
research using hypothetical scenarios. In addition, the rec-
ommended approaches are not generally used in standard
care. The BRISC study is designed to fill the gaps with an
evaluation of the effects of different formats of communi-
cating risks to counsellees facing real decisions in a clini-
cal setting. Results will be used to improve risk
communication in order to stimulate informed decision-
making among women with a family history of breast can-
cer.
The BRISC study is a field study; in other words, a clinical
trial which offers a unique opportunity to evaluate effects
of different formats of communicating risks to counsellees
facing decisions such as informing relatives who may also
be at risk, whether and when to start mammography
screening, and, assuming eligibility, whether to test for
mutations in BRCA1/2.
Quantitative outcome measures are collected using ques-
tionnaires at four points in time. The follow-up question-
naire is sent 6 months after the intervention, thereby
enabling medium-term effects to be detected. With this
comprehensive collected data, it will be possible to clarify
the various effects of different formats on four dimensions
evaluating the effectiveness of the risk communication
process. It is not inconceivable to expect that some for-
mats have positive effects on one of the dimensions and
negative effects on another dimension. Additionally, the
outcomes of this project will give a better understanding
of who, for example, as a function of cognitive capacity,
might or might not benefit from different formats.
Two control conditions are introduced in the BRISC
study: condition 5 in which the risk information is com-
municated in percentages as is commonly done in usual
care, and a second control condition (condition 6) in
which no intervention is given. With these two control
conditions, it is possible to distinguish between the effect
of repetition and the effect of giving the risks in a struc-
tured way on the one hand, and between the effects of giv-
ing the risks in a structured way in different formats on the
other.
Because the genetic counsellor involved has no role in the
inclusion of participants, selection bias is restricted, other
than from self-selection. Cluster-randomisation is applied
as it is too complex to randomise at the level of counsel-
lees because in that case a risk counsellor is asked to give
different risk formats of genetic risks to different counse-
lees on the same day. An exception is made for partici-
pants who are close family members.
The risk counsellors who give the intervention are not
involved in usual care. This will overcome concerns of
contamination bias. All risk counsellors are women, elim-
inating bias due to gender differences. The Latin Square
design and the control group, which is constructed in
addition to all condition rounds, both serve to eliminate
bias due to time. To achieve uniform risk communication
in the genetic counselling sessions, several precautions
have been taken (e.g. striving for a standard counselling
procedure, "counselling checklist", "checklist after stand-
ard counselling"), minimising confounding.
Some limitations of the BRISC study need to be
addressed. This study aims at improving women's under-
standing of the risks, and we acknowledge that there are
factors other than risk that can influence the decision-
making process. In addition, although several precautions
have been taken to achieve an optimal standardisation in
counselling and procedures, interactive features must be
acknowledged. Another limitation of this study is that it is
not possible to blind the genetic counsellors completely
because of the nature of the intervention. This applies to
the intervention allocation and to the age-related formats
due to anticipation of questions by the counsellee. Partic-
ipants are informed that the BRISC study concerned dif-
ferent kinds of risk counselling and are blinded.
Furthermore, although we would have preferred to test an
integrated intervention in standard counselling sessions,
it is not considered feasible, either ethically or practically,
to have the intervention done in a structured way by the
genetic counsellors themselves. If one of the formats
proves to be most effective, this format could be inte-
grated into the standard counselling session. Since mem-
bers of the research team provided the additional
consultations (interventions), implementation of a for-
mat in daily practice will need to receive further attention.
Finally, results may be extended to women with a per-
sonal history of cancer, other cancers, and also other dis-
eases and settings, but further study would be required.
Imprudent generalization should be avoided, although
the BRISC study may provide an indication for risk com-
munication in healthcare in general and cancer genetic
counselling in particular.
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